Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer

Showing 15 posts of 150 posts found.

Boehringer signs antibody myeloma R&D deal

May 10, 2010
Research and Development Boehringer, Cancer, Micromet, myeloma

Boehringer Ingelheim and US biotech company Micromet are to research and develop a new BiTE antibody to treat multiple myeloma. …

News

Boehringer enters the venture capital business

March 31, 2010
Research and Development, Sales and Marketing Boehringer, funding, venture capital

Boehringer Ingelheim is to tap into commercial opportunities in emerging technology by launching its own venture capital business. The Boehringer …

News
Boehringer building at night

Boehringer targets ‘genome guardian’ protein for cancer collaboration

January 19, 2010
Research and Development Boehringer, Cancer, Priaxon, genome

Boehringer Ingelheim has signed a worldwide deal with Munich-based pharma firm Priaxon to find novel treatments for cancer. The firms …

News
BI Centre_03 2

Boehringer’s ovarian cancer drug enters phase III

December 18, 2009
Research and Development, Sales and Marketing Boehringer, Cancer, ovarian

Boehringer Ingelheim has started a new phase III trial for its investigational cancer drug BIBF 1120. The LUME-Ovar-1 programme will …

News
Blog footer

Digital Pharma: A Year in Digital (5/5)

December 16, 2009
Medical Communications 2009, Boehringer, digi, digital pharma, year in review

Favourite use of digital (pharma)• Microsoft’s future of healthcare video. It’s their vision of the possibilities that I fell in …

Feature
BIC_03 2

Boehringer prepares for diabetes launch

December 3, 2009
Medical Communications Boehringer, DPP-4, diabetes

Boehringer Ingelheim has hired the London arm of international PR agency Weber Shandwick to handle the UK launch of its …

News

Digital Pharma: Boehringer’s bedtime stories

October 5, 2009
Medical Communications Boehringer, digi, digital pharma, restless legs

 

Feature

Pradaxa data boosts Boehringer

September 1, 2009
Research and Development, Sales and Marketing Boehringer, Pradaxa

Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …

News

Boehringer’s lung cancer candidate enters phase III

August 5, 2009
Research and Development, Sales and Marketing Boehringer, Cancer

Boehringer Ingelheim is to enter phase III studies with a candidate to treat a subset of patients with non-small cell …

News

Boehringer collaboration targets Alzheimer’s

June 18, 2009
Research and Development, Sales and Marketing Boehringer, CNS

Boehringer Ingelheim and Pennsylvania-based Vitae Pharmaceuticals have signed a global agreement to develop novel treatments for Alzheimer's. The disease currently …

News

Boehringer signs diabetes and obesity deal

May 14, 2009
Research and Development, Sales and Marketing Boehringer

Boehringer Ingelheim has signed a deal with German biopharma firm DeveloGen to research and develop treatments for diabetes and obesity. …

News

Spiriva leads charge for Boehringer

April 23, 2009
Sales and Marketing Boehringer, COPD

News

Boehringer Ingelheim takes the lead on Twitter

April 8, 2009
Medical Communications, Sales and Marketing Boehringer, Twitter, new media, social networking

The explosion in the popularity of Twitter is the latest buzz in online social networking, but most pharma companies are …

Feature

Boehringer’s cancer drug enters phase III

November 21, 2008
Sales and Marketing Boehringer, Cancer

Boehringer Ingelheim's new lung cancer drug Vargatef has entered phase III trials.The drug is part of the manufacturer's burgeoning oncology …

News

Spiriva partners defend drug’s safety

October 2, 2008
Sales and Marketing Boehringer, COPD, Spiriva, resp

Boehringer Ingelheim and Pfizer have released new data on Spiriva to defend the safety record of the chronic obstructive pulmonary …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023